
Viral Clearance
Description
Global Viral Clearance Market to Reach US$2.0 Billion by 2030
The global market for Viral Clearance estimated at US$749.0 Million in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 18.2% over the analysis period 2024-2030. Recombinant Proteins, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$467.7 Million by the end of the analysis period. Growth in the Blood and Blood Products segment is estimated at 15.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$215.9 Million While China is Forecast to Grow at 17.8% CAGR
The Viral Clearance market in the U.S. is estimated at US$215.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$319.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.0% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.
Global Viral Clearance Market - Key Trends & Drivers Summarized
Why Is Viral Clearance Critical for Biopharmaceutical Safety?
Viral clearance has become an essential component in the development and manufacturing of biologics, ensuring the removal of potential viral contaminants from biopharmaceutical products. The rise in monoclonal antibodies, recombinant proteins, and gene therapy products has significantly increased the focus on stringent viral safety protocols. Regulatory agencies such as the FDA and EMA mandate comprehensive viral clearance studies to validate manufacturing processes, driving demand for advanced viral inactivation and removal technologies. Biopharmaceutical companies are increasingly investing in viral clearance solutions, including filtration, chromatography, and chemical inactivation, to meet these regulatory requirements and ensure product safety.
How Are Technological Innovations Transforming Viral Clearance Methods?
The market is witnessing a surge in technological innovations aimed at improving the efficiency and reliability of viral clearance. Advances in high-throughput screening, automation, and AI-driven analytics are streamlining viral clearance processes, reducing turnaround times, and enhancing accuracy. Novel filtration techniques, including nanofiltration and membrane chromatography, are gaining traction for their superior viral removal capabilities. The growing adoption of single-use bioprocessing systems has also necessitated the development of compatible viral clearance solutions, ensuring seamless integration into modern manufacturing workflows. Additionally, the increasing role of continuous bioprocessing is driving the need for real-time viral clearance monitoring and validation technologies.
What Market Dynamics Are Influencing the Growth of Viral Clearance Services?
The demand for viral clearance services is expanding as pharmaceutical companies increasingly outsource biologics manufacturing to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The growing complexity of biologic drugs, coupled with stringent regulatory oversight, has led to an increase in specialized viral clearance testing services. The emergence of new biotherapeutics, including cell and gene therapies, has further intensified the need for reliable and scalable viral safety solutions. Additionally, the expanding vaccine development landscape, particularly in response to global health crises, is reinforcing the necessity of robust viral clearance strategies to ensure the safety and efficacy of immunotherapies.
The growth in the viral clearance market is driven by several factors, including the increasing number of biologics in the drug pipeline, advancements in viral removal technologies, and the rising outsourcing of biopharmaceutical manufacturing. The surge in gene and cell therapy development is further accelerating demand for comprehensive viral safety solutions. Additionally, the integration of AI and machine learning in viral clearance testing is enhancing process efficiency and regulatory compliance. The increasing adoption of single-use and continuous bioprocessing systems is also influencing market dynamics, necessitating innovative viral inactivation and filtration techniques. As regulatory standards continue to evolve, biopharmaceutical companies are investing in state-of-the-art viral clearance platforms to ensure product safety and expedite market approvals, driving sustained market growth.
SCOPE OF STUDY:The report analyzes the Viral Clearance market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Application (Recombinant Proteins, Blood and Blood Products, Vaccines, Other Applications); End-Use (Pharmaceutical & Biotechnology, CROs, Academic Research Institutes, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 41 Featured) -
- Avance Biosciences Inc.
- BSL BIOSERVICE Scientific Laboratories Munich GmbH
- Charles River Laboratories International, Inc.
- Clean Cells Inc.
- Lonza Group AG
- Merck KgaA
- SGS SA
- Sigma-Aldrich Corporation
- Texcell, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Viral Clearance – Global Key Competitors Percentage Market Share in 2025 (E)
- Global Economic Update
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Increasing Demand for Biologics and Biosimilars Driving Need for Robust Viral Clearance Strategies
- Rising Biopharmaceutical R&D Expenditures Fueling Adoption of Advanced Viral Clearance Technologies
- Growing Outsourcing Trends in Biologics Manufacturing Boosting Viral Clearance Service Demand
- Adoption of Advanced Chromatography and Nanofiltration Techniques Enhancing Viral Removal Efficiency
- Expanding Cell & Gene Therapy Pipeline Necessitating Stringent Viral Clearance Processes
- Increasing Regulatory Scrutiny on Biopharmaceutical Safety Accelerating Investment in Viral Clearance Methods
- Rise in Continuous Manufacturing and Single-Use Technologies Elevating Demand for Scalable Viral Clearance Solutions
- Advancements in High-Throughput and Automated Viral Clearance Testing Enhancing Market Growth
- Growing Prevalence of Zoonotic Viruses Driving Need for Improved Viral Clearance Approaches
- Expansion of Biosafety Testing Services Creating Lucrative Opportunities for Viral Clearance Providers
- Collaborations Between Biopharma Companies and Contract Testing Organizations Strengthening Market Expansion
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 2: World 6-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 4: World 6-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Blood and Blood Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World 6-Year Perspective for Blood and Blood Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 8: World 6-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 10: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World 6-Year Perspective for Pharmaceutical & Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 14: World 6-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 15: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 16: World 6-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 19: World Viral Clearance Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 22: USA Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 23: USA 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- CANADA
- TABLE 24: Canada Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 25: Canada 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 26: Canada Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- JAPAN
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 28: Japan Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 29: Japan 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 30: Japan Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 31: Japan 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- CHINA
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 32: China Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: China 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 34: China Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 35: China 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- EUROPE
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 36: Europe Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 37: Europe 6-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 38: Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: Europe 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 40: Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 41: Europe 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- FRANCE
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 42: France Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 43: France 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 44: France Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: France 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- GERMANY
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 46: Germany Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 47: Germany 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 48: Germany Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 49: Germany 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- ITALY
- TABLE 50: Italy Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: Italy 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 52: Italy Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 53: Italy 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- UNITED KINGDOM
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 54: UK Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 55: UK 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 56: UK Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: UK 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 59: Rest of Europe 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 61: Rest of Europe 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- ASIA-PACIFIC
- Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Asia-Pacific 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 65: Asia-Pacific 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- REST OF WORLD
- TABLE 66: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 67: Rest of World 6-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2025 & 2030
- TABLE 68: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Rest of World 6-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates